Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease

• Renáta Bor,

  Affiliation First Department of Medicine, University of Szeged, Szeged, Hungary

  ⨯
• Klaudia Farkas,

  Affiliation First Department of Medicine, University of Szeged, Szeged, Hungary

  ⨯
• Anna Fábián,

  Affiliation First Department of Medicine, University of Szeged, Szeged, Hungary

  ⨯
• Anita Bálint,

  Affiliation First Department of Medicine, University of Szeged, Szeged, Hungary

  ⨯
• Ágnes Milassin,

  Affiliation First Department of Medicine, University of Szeged, Szeged, Hungary

  ⨯
• Mariann Rutka,

  Affiliation First Department of Medicine, University of Szeged, Szeged, Hungary

  ⨯
• Mária Matuz,

  Affiliation Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary

  ⨯
• Ferenc Nagy,

  Affiliation First Department of Medicine, University of Szeged, Szeged, Hungary

  ⨯
• Zoltán Szepes,

  Affiliation First Department of Medicine, University of Szeged, Szeged, Hungary

  ⨯
• Tamás Molnár

  * E-mail: molnar.tamas@med.u-szeged.hu

  Affiliation First Department of Medicine, University of Szeged, Szeged, Hungary

  ⨯